Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cannabinoids derived from medicinal cannabis, including cannabidiol (CBD), may be useful for alleviating symptoms in people with kidney failure and are hepatically metabolised and not expected to be cleared by dialysis. CBD has been shown to improve anxiety and may be effective for pain and insomnia. It is non-intoxicating and has a high therapeutic index. However, despite growing interest in cannabidiol (CBD) for symptom management in kidney failure, pharmacokinetic data in this population remains limited with conflicting results from previous single-dose studies.
This phase 1b open-label study enrolled adults with kidney failure, including those receiving dialysis and those receiving conservative kidney management, who reported experiencing moderate-to-severe symptoms (a score of ≥ 4 on the Edmonton Symptom Assessment Score (revised)-Renal (ESASr-Renal), in at least one of the following symptom domains: pain, nausea, lack of appetite, itching, problem sleeping, restless legs, or tiredness). Participants received CBD sublingual wafers for 6 weeks with participant-led dose titration from 25mg daily, up to 300mg daily (although with flexibility for participants to go beyond that dose in the absence of side effects). Trough plasma concentrations of CBD and metabolites (6-OH-CBD, 7-OH-CBD, 7-COOH-CBD) were measured at weeks 3 and 6, and at 4 weeks post-treatment. Four participants completed an additional 8-hour pharmacokinetic substudy at week 6 following a single 200mg dose.
Twelve participants (3 female, 9 male) were enrolled (median age 69 years, range 54-85), of whom 10 were receiving dialysis (2 peritoneal dialysis, 8 haemodialysis) and 2 receiving conservative kidney management. Eleven participants completed the study, of whom 7 remained on CBD for 6 weeks (2 ceased due to lack of efficacy, 2 due to mild adverse effects). One participant died (unrelated to study treatment). The median daily dose of CBD was 300mg (range 25-400) after dose titration, with one participant later self-initiating further titration up to 1300mg daily. Steady-state trough concentrations of CBD and metabolites showed wide inter-individual variation but demonstrated proportional increases with increasing dose (R²=0.62-0.88). Detectable CBD persisted 4 weeks after final dose in 5 of 7 participants who completed 6 weeks of treatment, though concentrations were low (2-5 ng/mL). In the pharmacokinetic substudy (n=4), mean Cmax was 77.4 ng/mL (range 54.3-121.2), Tmax 3.3h (range 2.0-6.0), and AUC₀₋ₜ 305 ng·h/mL (range 226-401). These parameters were comparable to previous studies in populations without renal impairment.
CBD pharmacokinetics in people with kidney failure receiving dialysis or conservative management appeared similar to previously published data from the general population. The proportional dose-response relationship and tolerability of doses up to 400mg daily support further investigation of CBD in this population. Long-term persistence of low CBD levels requires monitoring in extended studies.
